Psychedelic Alpha - Commentary, Consultancy, Community
We provide information, research, news and exclusive interviews from the emergent psychedelic sector in one place. Cut through the ‘shroom stock’ noise with Psilocybin Alpha.| Psychedelic Alpha
We provide information, research, news and exclusive interviews from the emergent psychedelic sector in one place. Cut through the ‘shroom stock’ noise with Psilocybin Alpha.| Psychedelic Alpha
Your one-stop source for the latest coverage of psychedelics in the media: from policy and culture through to research and business.| Psychedelic Alpha
Psychedelic Alpha’s Josh Hardman speaks with clinical psychologist and trauma researcher Dr. Samuli Kangaslampi about how psychedelics affect autobiographical memory. They discuss the historical…| Psychedelic Alpha
Topline results from the latest in our series of psychedelics investor surveys. For detailed analysis, subscribe to Pα+ today.| Psychedelic Alpha
MindMed’s Phase 2b LSD (MM120) for generalised anxiety disorder (GAD) study, published in JAMA earlier this month, shows promising efficacy and a favourable safety profile. Here…| Psychedelic Alpha
This morning, the UK’s Royal College of Psychiatrists published a Position Statement on psychedelics and related substances for medical use. Here, we briefly unpack the statement, as well as related…| Psychedelic Alpha
We present the psychedelic drug development pipeline in two ‘bullseye chart’ formats, as of Q3’2025.| Psychedelic Alpha
From a long stint at the European Medicines Agency’s (EMA) Office of Therapies for Neurological and Psychiatric Disorders to her present-day practice as a clinical psychiatrist at leading cancer…| Psychedelic Alpha
The FDA is pushing researchers to reduce their use of animal models and instead adopt ‘new approach methodologies’, like organoids and AI modelling. Here, Dr. Alaina Jaster speaks with psychedelic…| Psychedelic Alpha
